This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epratuzumab's B-Cell Modulation Effect Elucidated In Preclinical Study

-- Unique Mechanism of Action Involves Transfer of Key B-Cell Receptor Proteins From B Cells to Other White Blood Cells -- -- Study Presented at the 2012 Annual Meeting of the American Society of Hematology --

ATLANTA, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body.

Epratuzumab is a humanized antibody targeting the CD22 receptor on B cells. Originally developed by the Company, the anti-CD22 antibody has previously demonstrated therapeutic activity in non-Hodgkin lymphoma (NHL) and systemic lupus erythematosus (SLE), and is currently in two Phase III clinical trials for the treatment of SLE (EMBODY 1 and EMBODY 2). Epratuzumab is being developed in SLE by UCB who hold the worldwide development rights for this compound in autoimmune diseases.The Company retains all rights in oncology.

While it is known that epratuzumab causes a reduction of about 45% of circulating B cells, in contrast to veltuzumab and other anti-CD20 antibodies that deplete more than 90% of B cells, the mechanism of action of epratuzumab in SLE remains to be fully understood.

Peripheral blood mononuclear cells (PBMCs) from normal donors, SLE patients, and of NHL cells spiked into normal PBMCs were used in this preclinical study. When bound to the CD22 receptor on B cells, epratuzumab promptly induced the transfer of key proteins associated with the B-cell receptor complex from B cells to other white blood cells such as monocytes, natural killer cells and granulocytes. In addition to CD22, receptors that were transferred include CD19, CD21 and CD79b. Interestingly, SLE patients currently on epratuzumab therapy showed significantly lower levels of CD22, CD19 and CD21, compared to treatment-naive patients.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs